iRhythm Technologies Inc IRTC 深 滬
等待開盤 09-06 09:30:00 美东时间
181.05
-1.120
-0.61%
華盛通- 最 高183.95
- 今 開182.36
- 成交量 35.01万股
- 最 低 180.18
- 昨 收 182.17
- 總市值 58.17亿
- 52周最高 183.95
- 市盈率 靜 --
- 換手率 1.09%
- 52周最低 55.92
- 委 比 99.30%
- 總股本 3212.78万
- 歷史最高 286.19
- 量 比 0.88
- 振 幅 2.07%
- 歷史最低 22.25
- 每 手 1
- 風險率 17.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多iRhythm's Zio Home-Based Monitoring Shows Faster AFib Diagnosis In AMALFI Trial; ESC 2025 And JAMA Publication Highlight Results
Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether
08-29 19:03
AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
Oxford University-led AMALFI trial results, presented at ESC Congress 2025 and published in JAMA, demonstrate that home-based Zio long-term monitoring improves AFib detection and diagnosis time in a UK population at moderate to high stroke risk. The study enrolled 5,040 participants, showing a 6.8% AFib detection rate vs 5.4% in usual care, with faster diagnosis times (103 vs 530 days). The remote, home-based strategy, using Zio's wearable ECG pa...
08-29 11:00
Needham Maintains Buy on iRhythm Technologies, Raises Price Target to $193
Needham analyst David Saxon maintains iRhythm Technologies (NASDAQ:IRTC) with a Buy and raises the price target from $180 to $193.
08-28 18:34
美股大行评级 | Analog Devices获大摩、小摩、富国银行等四家机构"超配"评级，目标价最高升至310美元
今日重点评级关注：摩根大通：维持Analog Devices"超配"评级，目标价从300美元升至310美元；花旗：维持梅特勒-托利多"买入"评级，目标价从1400美元升至1600美元
08-22 09:57
Where iRhythm Technologies Stands With Analysts
In the latest quarter, 7 analysts provided ratings for iRhythm Technologies (NA...
08-20 22:02
iRhythm Technologies to Participate in Upcoming Investor Conferences
iRhythm Technologies, Inc. announced that its management team will present at three upcoming investor conferences: Wells Fargo 2025 Healthcare Conference on Sept 3, Morgan Stanley Global Healthcare Conference 2025 on Sept 9, and Baird 2025 Global Healthcare Conference on Sept 10. Webcasts will be available on the company’s investor website. iRhythm focuses on creating digital health solutions to detect, predict, and prevent diseases, using wearab...
08-20 20:30
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage
Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target.
08-19 02:25
iRhythm shares are trading lower after Spruce Point Capital Management issued a 'Strong Sell' opinion on the stock.
iRhythm shares are trading lower after Spruce Point Capital Management issued a...
08-18 21:08
AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority
The AVALON study, involving 428,707 commercially insured patients, demonstrates that the Zio LTCM service surpasses other cardiac monitoring methods in diagnostic yield, speed, reducing cardiovascular events, and lowering healthcare costs. Key findings include a 26.5% arrhythmia diagnosis rate, fastest time to diagnosis (9 days), lowest retest rate (3.1%), and minimal healthcare resource utilization. This study reinforces the clinical superiority...
08-18 12:05
美股大行评级 | 花旗、小摩分别上调苹果目标价；瑞穗上调Robinhood目标价从99美元升至120美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从46美元升至52美元；BTIG：维持Strategy"买入"评级，目标价从620美元升至700美元
08-04 09:30
